Riluzole

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Nov 1, 1999 → Jul 1, 2004

NCT ID

NCT00277602

About Riluzole

Riluzole is a phase 3 stage product being developed by Sanofi for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00277602. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 10 similar drugs in Huntington Disease were approved

Approved (1) Terminated (2) Active (7)

✅TetrabenazineLundbeckApproved

🔄Votoplam (blinded) + PlaceboNovartisPhase 3

🔄RO7234292 (RG6042)RochePhase 3

🔄RO7234292 + PlaceboRochePhase 3

🔄DimebonPfizerPhase 3

❌Dimebon (latrepirdine)PfizerPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00542412	Approved	Completed	Jan 1, 2001	Dec 1, 2004	Amyotrophic Lateral Sclerosis
NCT00277602	Phase 3	Completed	Nov 1, 1999	Jul 1, 2004	Huntington Disease

Competing Products

20 competing products in Huntington Disease

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + Matching Placebo	Eli Lilly	Phase 2	35
Votoplam (blinded) + Placebo	Novartis	Phase 3	47
Votoplam	Novartis	Phase 2	39
Branaplam + Placebo	Novartis	Phase 2	27
AFQ056 + Placebo	Novartis	Phase 2	27
RO7234292 (RG6042)	Roche	Phase 1	29
Tominersen + Placebo	Roche	Phase 2	39
RO7234292 (RG6042)	Roche	Phase 3	40
RO7234292 (RG6042)	Roche	Phase 2	35
RG6496 + Placebo	Roche	Phase 1	36
RO7234292 + Placebo	Roche	Phase 3	40
PF-02545920 + PF-02545920	Pfizer	Phase 2	35
Dextromethorphan + Dimebon + Dextromethorphan	Pfizer	Phase 1	29
Dimebon	Pfizer	Phase 3	40
Dimebon (latrepirdine)	Pfizer	Phase 3	32
20 mg BID of PF-02545920	Pfizer	Phase 2	27
PF-02545920 + Placebo + PF-02545920 + Placebo	Pfizer	Phase 2	35
ALN-HTT02 + Placebo	Alnylam Pharmaceuticals	Phase 1	33
Tetrabenazine	Lundbeck	Approved	36
Valbenazine	Neurocrine Biosciences	Phase 3	41